Home › Gastrointestinal Cancers › Illinois
Gastrointestinal Cancers clinical trials in Illinois
7 studies for Gastrointestinal Cancers are looking for participants at sites in Illinois.
Cities in Illinois
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- and 41 more
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07283939Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Illinois Cancer Specialists, Arlington Heights
- Illinois CancerCare - Bloomington, Bloomington
- Illinois Cancer Specialists, Chicago
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07222800A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- GSK Investigational Site, Chicago
- GSK Investigational Site, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07218926DESTINY-PANTUMOUR04
- Research Site, Decatur
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
- Northwestern University, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07594626Telephone Support in Advanced Gastrointestinal Cancer
- Northwestern Medicine, Chicago
Recruiting
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT06532877A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- University of Chicago, Chicago
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.